LEAP2 Hormone Analog Enhances Weight Loss and Prevents Rebound When Combined with Semaglutide
New research shows combining LEAP2 with semaglutide produces superior weight loss and prevents weight regain in mice.
Summary
Researchers developed a long-acting version of LEAP2, a liver hormone that blocks ghrelin receptors and reduces appetite. When combined with semaglutide (Ozempic/Wegovy), this dual therapy produced enhanced weight loss and crucially prevented weight regain after treatment stopped. The LEAP2 analog worked by reducing food intake while preserving energy expenditure, without causing behavioral aversion. This combination approach addresses a major limitation of current weight loss drugs - rapid weight regain after discontinuation.
Detailed Summary
Weight regain after stopping GLP-1 drugs like semaglutide represents a critical challenge in obesity treatment, with over 50% of patients discontinuing within the first year. This study explored whether combining semaglutide with LEAP2, a recently discovered liver hormone that naturally opposes ghrelin's appetite-stimulating effects, could enhance weight loss durability.
Researchers created a long-acting LEAP2 analog (LA-LEAP2) and tested it alone and in combination with semaglutide in obese mice fed high-fat diets. The LA-LEAP2 works by blocking ghrelin receptors in the brain, particularly in neurons that drive hunger and food-seeking behavior.
LA-LEAP2 alone produced significant weight loss through reduced food intake while preserving energy expenditure - a crucial advantage over approaches that simply slow metabolism. When combined with semaglutide, the dual therapy showed superior weight reduction in some experiments and, most importantly, dramatically reduced weight regain compared to semaglutide alone.
The combination therapy targets complementary pathways: semaglutide activates satiety signals through GLP-1 receptors, while LA-LEAP2 blocks hunger signals through ghrelin receptor antagonism. This dual approach addresses both sides of appetite regulation. Importantly, behavioral tests confirmed LA-LEAP2 caused no aversion or discomfort, suggesting good tolerability.
These findings suggest LEAP2 analogs could serve as valuable adjuncts to existing weight loss medications, potentially improving long-term success rates by preventing the weight regain that typically follows treatment discontinuation. The research provides a promising new strategy for sustainable obesity management.
Key Findings
- LA-LEAP2 analog reduced body weight in obese mice through decreased food intake and preserved energy expenditure
- Combined LA-LEAP2 and semaglutide therapy prevented weight regain more effectively than semaglutide alone
- LA-LEAP2 showed no behavioral aversion or discomfort in safety testing
- The combination targets complementary appetite pathways - ghrelin blockade plus GLP-1 activation
- Treatment effects were sustained without metabolic adaptation or tolerance development
Methodology
Researchers used diet-induced obese male C57BL/6J mice treated with various doses of LA-LEAP2 alone or combined with semaglutide. Studies included dose-response testing, behavioral assessments, metabolic measurements, and weight regain protocols with appropriate vehicle controls.
Study Limitations
Studies were conducted only in male mice, limiting generalizability. The optimal dosing and timing for human translation remains unclear. Long-term safety data for LEAP2 analogs in humans is not yet available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.